Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Shirish M. Gadgeel, Dong Wan Kim, Alice T. Shaw, Fabrice Barlesi, Lucio Crinò, Filippo de Marinis, Ravindra Gupta, James Chih-Hsin Yang, Anne-Marie C. Dingemans, Sai-Hong Ignatius Ou, Vlatka Smoljanovic, Shiyao Liu, Mathias Schulz
Publikováno v:
Lung Cancer: Targets and Therapy. 10:125-130
Introduction Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.
Autor:
Cesare Gridelli, Filippo de Marinis, Vito Barbieri, Maria Rita Migliorino, Massimo Barberis, Fabiana Vitiello, Giampiero Romano, Stefano Gasparini, Alfonso Marchianò, Francesca Spinnato
Publikováno v:
Expert Review of Respiratory Medicine. 13:217-228
In the era of personalized cancer therapy, the sampling of adequate tumor tissue for histologic diagnosis and genomic profiling is crucial, not only at the initial diagnosis but also in the event of resistant and recurrent disease when sequential bio
Autor:
Gianluca Spitaleri, Filippo de Marinis, Niki Karachaliou, Chiara Catania, Antonio Passaro, Chiara Lazzari, Alessia Pochesci, Rafael Rosell
Publikováno v:
OncoTargets and therapy
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung can
Publikováno v:
Expert Review of Anticancer Therapy. 16:799-801
Autor:
Filippo de Marinis, Cristina Noberasco, Roberto Biffi, Chiara Catania, Chiara Lazzari, Massimo Barberis, Francesca Toffalorio, Gianluca Spitaleri, Caterina Fumagalli, Tommaso De Pas
Publikováno v:
OncoTargets and therapy
The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achie